NeuSpera Medical

7 articles with NeuSpera Medical

• 

  Money on the Move: July 14 – 21

  7/21/2021

  More money means more progress for potentially life-saving therapies. Here's a peek at some biopharma companies adding to their books this week.

• Neuspera Medical Announces Close of a $65M Series C Equity Financing

  7/20/2021

   Neuspera Medical Inc. today announced the closing of the company's $65 million series C equity financing. The Series C round was co-led by Vertex Ventures HC and Treo Ventures. 

• 

  Clinical Catch-Up: June 8-12

  6/15/2020

  It was a fairly busy week with clinical trial updates and announcements. Here’s a look.

• Neuspera Medical Completes First Implants of its Neuromodulation Device in its two-stage Pivotal Clinical Trial to treat Urinary Urgency Incontinence

  6/10/2020

  Neuspera Medical Inc., a privately held, clinical stage medical device company, today announced the completion of the first chronic clinical implants of the Neuspera Neuromodulation System on the sacral nerve.  The ultra-miniaturized device

• Neuspera Medical Receives Investigational Device Exemption for Its Ultra-Miniaturized Implantable Device

  12/10/2019

  Neuspera Medical Inc., a clinical stage, private, venture capital backed neuromodulation company, announced the receipt of an Investigational Device Exemption from the FDA – enabling the company to conduct the first long-term clinical trial of its ultra-miniaturized neuromodulation platform.

• Neuspera Medical Announces Final Close of $26M Series B Equity Financing

  2/20/2019

  Neuspera Medical Inc., a clinical stage, private venture capital backed neuromodulation company, announced the final closing (2nd tranche) of the company's Series B equity financing.

• Neuspera Medical Announces Initial Close of $26M Series B Equity Financing

  1/24/2018

  The $26M financing was led by 6 Dimensions Capital with all existing investors from Series A also participating including Action Potential Venture Capital and Windham Venture Partners.